Enliven Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Enliven Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Enliven Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$27.1M, a 11.6% decline year-over-year.
  • Enliven Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$100M, a 41.5% decline year-over-year.
  • Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$83.5M, a 115% decline from 2022.
  • Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$38.8M, a 56.7% decline from 2021.
  • Enliven Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$24.8M, a 40.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$83.5M -$44.7M -115% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 -$38.8M -$14M -56.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$24.8M +$16.9M +40.6% Jan 1, 2021 Dec 31, 2021 8-K 2023-06-23
2020 -$41.7M -$17.6M -72.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 -$24.1M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.